Roche Holding AG ADR Stock

Price

Target price

/ Tradegate WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Your prediction

Roche Holding AG ADR Stock

A loss of -1.550% shows a downward development for Roche Holding AG ADR.

Based on 3 Buy predictions and 2 Sell predictions the sentiment towards Roche Holding AG ADR is rather balanced.

With a target price of 45 € there is a slightly positive potential of 8.68% for Roche Holding AG ADR compared to the current price of 41.41 €.

So far the community has only identified positive things for Roche Holding AG ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

What does Roche do?

Pros and Cons of Roche Holding AG ADR in the next few years

Pros

M***** P*******

G***** c******* t* c**********

W********* I********* f** t** n*** y****

Cons

C******** o* t** e**********

B****

S********** s********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of Roche Holding AG ADR vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
Roche Holding AG ADR
Novartis AG ADR
Bayer AG ADR
Novo Nordisk A/S ADR

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2023-11-10

Roche Holding AG (RHHBY), a multinational healthcare company based in Switzerland, stands strong with its broad and diversified portfolio. A closer look into Roche's financial statements prominently reveals a robust business model underpinned by substantial revenues and a profitable margin.

Observing Roche's income statements over the past three years, the figures showcase an impressive gross profit with a steady upward trend. This consistency strongly indicates a robust operating model and proficient managerial efficiency. With increasing net income, the company seems to have experienced notable business and financial growth, reinforcing the credibility of the investment.

Roche also earns recognition for its significant investment in research and development, crucial for pharmaceutical companies. The data reveals a substantial annual expenditure, reflecting Roche's commitment to future growth and revolutionizing pharmaceutical breakthroughs, leading to a sustainable competitive advantage.

Feedback